Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva

Format: Webcourse
Credit(s): 1.00 (60 min)
Release Date: Oct 01, 2020
Expiration Date: Oct 01, 2021
Credit Type(s):
  • CME / AMA PRA Category 1 Credit™
  • MOC / ABP MOC Points


As a rare disease, fibrodysplasia ossificans progressiva (FOP) poses substantial diagnostic and treatment challenges for pediatricians and pediatric orthopedists. It is frequently confused with other development bone diseases due to similar presentation, and treatment options are lacking. Currently, treatment of FOP is limited to symptomatic management of disease flare-ups. In recent years, however, improved understanding of the genetics and pathophysiology of FOP have led to improvements in diagnosis and treatment, as well as the identification of multiple new therapeutic targets. Novel agents that have demonstrated efficacy in minimizing disease symptoms and slowing progression of disease are currently in late-stage clinical trials and may soon be available for FOP treatment.

This activity, Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva, will provide clinicians with expert advice and guidance on how to identify and diagnose FOP in their patients, current best practices for FOP management, and the most up-to-date information on novel therapies currently in clinical trial for treatment of FOP.


Welcome and Introduction

Increasing Awareness of FOP

Ensuring Optimal FOP Treatment

Understanding the Latest Advances in FOP Care

Q&A Session and Activity Roundup


The intended audiences for this initiative are pediatricians and pediatric orthopedists, the clinicians who diagnose and manage patients with FOP.


This program is designed to address ACGME and NAM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

At the conclusion of this education, participants should be able to:

  • Distinguish patients with FOP using the latest recommendations and criteria
  • Develop effective FOP treatment plans which incorporate the most recent clinical evidence
  • Evaluate the latest safety and efficacy data with FOP agents in late-stage development


Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.


Physicians – The Potomac Center for Medical Education designates this enduring materials for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this activity, please email: contact@potomacme.org.


Peter Kannu, MB ChB, PhD, DCH, FRACP, FRCPC
Associate Staff
The Hospital for Sick Children and Peter Gilgan Centre for Research and Learning
Chair of Medical Genetics
University of Alberta
Toronto, Canada
Peter Kannu, MB ChB, PhD, DCH, FRACP, FRCPC is a Paediatrican and Clinical Geneticist who works on diseases affecting the skin and bones. After completing medical school and paediatric training in New Zealand, he moved to the Murdoch Childrens Research Institute/Royal Children’s Hospital in Melbourne where he trained in Clinical Genetics. He then went on to complete a PhD in cell matrix biology at the University of Melbourne. Prior to Edmonton, he worked as a Consultant Clinical Geneticist at the Victorian Clinical Genetics Service in Australia and Queen’s University in Ontario. In 2010, he was recruited to the Hospital for Sick Children in Toronto because of his specialist skills in the human chondrodysplasias. At SickKids, he developed the first Canadian multidisciplinary genodermatosis clinic in collaboration with paediatric dermatologists. He is now the Chair of Medical Genetics at the University of Alberta.
Anna Rabinowitz, MD, CPPS
Clinical Assistant Professor
Department of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Anna Rabinowitz, MD, CPPS is a pediatric and adult anesthesiologist in Philadelphia, PA. She is a graduate of the University of Pennsylvania School of Medicine and completed residency in Anesthesiology at the University of California-San Francisco. She then returned to Philadelphia to complete a fellowship in Pediatric Anesthesiology at the Children’s Hospital of Philadelphia before joining the faculty at Thomas Jefferson University in 2012. Areas of interest include Patient Safety Science, neurovascular anesthesia, and the perioperative management of patients with FOP.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. To receive MOC points, you MUST complete the posttest and evaluation. For ABP MOC points, your information will be shared with the ABP through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABP records. For questions regarding CME credit or the evaluation, please email contact@potomacme.org.


The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.


Peter Kannu, MB ChB, PhD, DCH, FRACP, FRCPC: Honoraria: Alexion, Ipsen

Anna Rabinowitz, MD, CPPS: Nothing to disclose


Chelsey Goins, PhD; Katie Propst, PhD: Nothing to disclose


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.


Jointly provided by the Potomac Center for Medical Education and Rockpointe



This program is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.


Understanding and Addressing the Global Spread of the COVID-19 Infection: A Clinician’s Guide

Learn More

Obesity and COVID-19 in the Outpatient Setting: What Clinicians Need to Know

Learn More

Expert Updates on Diagnosing and Managing Eosinophilic Granulomatosis with Polyangiitis

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy